logo
Current and Future AI Uses in Dermatology: An Expert's View

Current and Future AI Uses in Dermatology: An Expert's View

Medscape04-06-2025
Roxana Daneshjou, MD, PhD, is one of the leading experts on artificial intelligence (AI) in American dermatology. Daneshjou, assistant professor of biomedical data science and dermatology at Stanford University, Stanford, California, leads landmark AI studies, is an associate editor of the journal NEJM AI , and gives presentations about the topic, including one at the recent Society for Investigative Dermatology (SID) 2025 annual meeting where she starkly warned colleagues that 'dermatologists who use AI will replace dermatologists who don't.'
Roxana Daneshjou, MD, PhD
So one could assume that Daneshjou embraces AI in her clinical practice. But she doesn't — not quite yet. While AI is helpful with office tasks that involve writing, she said, it's not currently good enough at handling tasks, such as evaluating skin lesions or helping solve diagnostic riddles.
'You should only use it for tasks where you can easily catch errors and rectify them. You shouldn't use it when you're not sure of the answer or the next step because you could be badly misled,' she said in an interview with Medscape Medical News .
But just wait. 'Eventually, once we have valid, well-validated AI tools that can help with diagnosis and triage, they're going to become essentially standard of care,' Daneshjou said.
The following are excerpts from the interview with Daneshjou about the present and future of AI in dermatology.
What do you mean when you say, 'Dermatologists who use AI will replace dermatologists who don't'?
Daneshjou: That's actually a rehashed phrase originally coined by Curt Langlotz, a radiologist who made the same claim about radiologists. The point is that dermatologists aren't going anywhere. AI is not replacing dermatologists. It's that dermatologists who use AI will replace dermatologists who don't.
Will some dermatologists be left behind?
Daneshjou: Medicine always evolves. There was a time when we didn't have advanced imaging technologies like CT scans and MRIs. And think about how many dermatologists now use electronic health records (EHRs) vs writing everything down by hand. There are still some people writing things by hand, but physicians who can use EHRs have largely replaced those who can't.
This isn't a new phenomenon. Whenever new technology comes along, it becomes incorporated into medical practice, and those who learn to adapt and adopt it eventually replace those who don't.
Is there fear and denial in the dermatology community about AI?
Daneshjou: There's fear, but there's also enthusiasm — sometimes enthusiasm to the point of using things that aren't ready for prime time. In my SID talk, I discussed how it's not safe to use large language models [AI] — LLMs — for any clinical task where you don't know the answer or can't validate it quickly. These models can have errors that are difficult to catch because the outputs look so convincing.
Can you give an example of how using LLMs clinically might get a dermatologist in trouble?
Daneshjou: In my presentation, I showed AI being asked to calculate a RegiSCAR score for a patient. It gives an output that looks really convincing but has some of the scores wrong. If you didn't know the RegiSCAR score yourself, you might not catch that mistake. Similarly, if you ask about medication dosing, sometimes AI gets it right. But research papers show it can get dosing wrong. If you're not certain of the answer, you shouldn't use an LLM for that task.
That's different from giving it bullet points and saying, 'Follow these bullet points to draft a prior authorization letter' or 'Write an after-visit summary for my patient' about a disease you're well-versed in, and you can verify [the text] for accuracy.
Are there reliable clinical uses for AI now?
Daneshjou: First, I should note that publicly facing models aren't Health Insurance Portability and Accountability Act (HIPAA)–compliant, so you have to be careful about putting patient information in them. Some institutions like Stanford have HIPAA-compliant versions internally.
I'd be very wary of using these models for diagnosis and treatment because they can say things that are wrong. I've heard dermatologists say they've put patient images into these models to get a differential diagnosis, which I would strongly advise against — both for HIPAA concerns and because the outputs aren't reliable.
What about 'vision language' models (VLMs) in dermatology that are trained on skin images and could potentially be used for tasks such as identifying lesions?
Daneshjou: The VLMs we've tested perform worse than the LLMs. They're even more in the research realm.
Are current AI systems actually good at categorizing skin lesions?
There are many papers claiming they're good, but there's not much prospective trial data validating that performance. We need more trial data proving that a particular model will continue to perform well in a clinical setting.
So AI isn't ready for prime time in diagnosis and treatment?
Daneshjou: That's correct. It's more useful in a supportive role — helping with writing or editing text.
You worked on a 'red teaming' event that assigned attendees — engineers, computer scientists, and health professionals such as dermatologists to assign medical tasks to AI and ask questions. The results were published in Nature in March 2025. What did you discover?
Daneshjou: We found that across all models tested, there was an error rate of around 20%. As our chief data scientist at Stanford likes to joke, 'You can use large language models for any task where a 20% error rate is acceptable.'
Where do you think AI and dermatology are headed next?
Daneshjou: Image-based models will eventually get good enough to earn US Food and Drug Administration clearance. But my concern is this will happen without the creators having to prove the models work across diverse skin tones — an incredibly important part of validation.
Our research has shown that most image-based AI models exclude diverse skin tones in their training and testing. We're also going to see more multimodal models — ones that incorporate diverse information like images, text, and molecular data — to provide outputs or risk assessments. That's where AI is heading generally, not only just focusing on text or images alone but also taking information from multiple modalities the way humans do.
How often do you use AI in your clinical practice?
Daneshjou: Not very much. I run a research lab, so I use it extensively in research. I've used it to help with grant writing and to analyze recommendation letters I've written, asking it to identify weaknesses so I can improve them. Clinically, I've shown my nurse how to use our secure AI to draft prior authorization letters or rebuttals to insurance [rejections]. But otherwise, I don't really use it in clinic.
You've discussed how AI handles clinical vignettes vs real patients. What should dermatologists understand about this?
Daneshjou: Headlines often misrepresent reality. They'll say, 'AI models can diagnose patients.' But in reality, these models were given very nicely packaged vignettes and were able to provide a diagnosis.
Patients don't come as nicely packaged vignettes. In real clinical practice, I have to ask, 'What's going on?' I have to do the skin check, identify lesions, gather history, and ask about duration, symptoms, occupation, and sun exposure. I have to collect all this information and make a judgment.
Sometimes, the history doesn't match what you see, so you have to use clinical reasoning. This kind of clinical reasoning isn't what they're testing in research papers that claim AI can diagnose patients.
Would you recommend using AI at all for generating differential diagnoses?
Daneshjou: I'm not using AI just to use it. I need a specific reason why I think it will help me. For example, if I'm writing a grant and want a summary of one of my own research papers, I might ask it to write a first draft that I can edit because I know my own research well enough to verify what's correct. But I'm not using it to develop differentials for my patients.
What would you advise dermatologists who want to adapt to AI but don't know where to start?
Daneshjou: The American Academy of Dermatology (AAD) has AI boot camp videos. At the annual AAD meetings, the AAD offers educational sessions on AI.
If you look in the Journal of the American Academy of Dermatology , there are Continuing Medical Education reviews that the AAD's Augmented Intelligence Committee has written to educate dermatologists about AI technologies and what to watch for.
A few years ago, this content was sparse. But there's been a concerted effort to create educational materials for dermatologists.
What would you tell dermatologists who are agonizing about AI?
Daneshjou: I see people posting on LinkedIn what I would call outrageous claims based on research papers. They'll say, 'This research paper shows we have autonomous AI agents that can treat patients,' but when you read the actual paper, it doesn't show that at all. Often, the hype doesn't match the reality on the ground.
And what about those who think AI is overblown and not worth worrying about?
Daneshjou: Claims about AI replacing physicians or dermatologists are indeed overblown. But this is definitely something dermatologists will have to adapt to. It's eventually going to become part of practice in some ways.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cynthia Bailey, Toya Johnson, Shay Johnson: Fibroid Nightmares & Hope
Cynthia Bailey, Toya Johnson, Shay Johnson: Fibroid Nightmares & Hope

Black America Web

time15 minutes ago

  • Black America Web

Cynthia Bailey, Toya Johnson, Shay Johnson: Fibroid Nightmares & Hope

Source: John Lamparski / Getty 'I almost lost my life,' admitted Love & Hip Hop: Miami alum Shay Johnson, recalling how heavy bleeding went unchecked for months. ' I thought I was just stressed, working too much. I was drinking, not eating right, and ignoring my body. Then I collapsed. Doctors found fibroids the size of grapefruits, and I needed a blood transfusion.' Now Johnson says she's cut back on alcohol, overhauled her diet, and prioritizes sleep. 'I can't keep living like I'm invincible. I've got a daughter now. My career's growing — I have to be here for her, and that starts with me taking care of me.' Her path to motherhood was paved with pain and heartbreak. After undergoing a myomectomy – the surgical removal of fibroids – she revealed: We care about your data. See our privacy policy. 'They didn't tell me I could never conceive vaginally because of the surgery —I cried on social media because I wanted that womanly experience. But I got my beautiful baby—and I want one more.' Transforming her struggle into purpose, Shay now champions women's health through her own wellness brand, The Healthy Hand , Fibroids affect 26 million American women, disproportionately impacting Black women. The Fibroid Fighters Foundation, created by Dr. Yan Katsnelson, works to end the epidemic of unnecessary hysterectomies and educate women about minimally invasive treatments like UFE. Every ten minutes in the U.S., twelve hysterectomies are performed—and shockingly, nine of them are unnecessary. READ MORE STORIES: Cynthia Bailey, Toya Johnson, Shay Johnson: Fibroid Nightmares & Hope Jagged Edge Unveils 11th Album Trilogy and Line Dance Remix MFT: Jane Handcock Remembers First Marriage Her Music Saved Reality stars Cynthia Bailey, Toya Johnson and Shay Johnson joined an awareness event in New York at the Fibroid Fighters Foundation's Your Health in Full Bloom event—a gathering created to amplify stories like theirs and introduce women, especially Black women, to treatments beyond hysterectomy. Their efforts are part of a broader push to destigmatize fibroids and ensure women know all their options—not just the most invasive ones 'I found out about fibroids when I was pregnant with my daughter, Noelle,' Cynthia Bailey recalled. 'They just kept growing and growing. I had super heavy periods, bloating—I was always on the celebrity baby bump list for a child I wasn't pregnant with. I had a bunch of fibroid babies inside of me, and lipo can't help that.' Bailey eventually underwent UFE, a procedure that shrinks fibroids without surgery. 'Please make sure you always ask for UFE first,' she urged. 'A hysterectomy should always be the last resort.' Beyond advocating for women's health, Bailey is stepping into powerful new roles. Fresh off season 16 of The Real Housewives of Atlanta, she's filming a short drama titled Diamond where she plays a mother battling heroin addiction—her most challenging acting role yet. 'I wanted to do something where I completely lose myself in a character,' she said. And yes, even queens have bad habits 'I don't drink enough water, I'm a late-night eater, and I have tons of supplements I don't take as regularly as I should,' she admitted with a laugh. RELATED STORIES: 'No One Should Have to Go Through This': Venus Williams On Fibroids & Fighting To Be Heard Sis, It's Not Too Late: The Rise Of Black Motherhood After 40 Inside Her Story: How To Identify And Prevent Fibroids Toya Johnson: 'If You Want That Flat Stomach, Get UFE' Toya Johnson knows the pain fibroids bring. 'I had them twice. I got a myomectomy and later did UFE. My stomach would bloat like I was four months pregnant—and liposuction doesn't fix that,' she explained. Johnson uses her platform to educate women who, like her, once didn't know what was happening to their bodies. 'Walk, work out, stay active—but most importantly, take care of yourself. If you have fibroids, get that UFE if you can.' As for what's next? 'I have a new book coming out called ' Forties Kicking My Ass ,'' she revealed. 'When you hit 40, life changes—your vision changes, your energy changes. But it's all about growth, opening up, and being vulnerable.' The reality star, now married, shared her secret to a happy relationship: 'Date the person you're with. Be friends. Communicate. A person can't read your mind—you have to walk communication, not just talk it.' Her 'bad habit'? 'Always wanting to be right. We're not always right, but who wants to hear that?' she joked. Source: John Lamparski / Getty Shay Johnson: From Pain to Purpose 'I never even heard of fibroids until I had them,' said Shay Johnson, who has become one of the loudest voices in fibroid awareness. 'That's ridiculous. This should have been talked about in our families, our communities, on social media. Women deserve to know their options.' Johnson's first surgery, a myomectomy, allowed her to conceive her daughter—but left her devastated when she learned she could never give birth vaginally. Now single and focused on her wellness brand, The Healthy Hand, Johnson is filming new episodes of Love & Hip Hop and raising her daughter to be a boss. 'She just launched her own elderberry gummy line—I want to teach her business ethics young so she can take over when I'm gone.' Johnson confessed to a strange quirk: 'Because I'm anemic, I brush my teeth ten times a day with baking soda. It's horrible, but I can't stop!' Cara Maria Sorbello: Fighting Fibroids and Winning Challenges MTV's The Challenge champion Cara Maria Sorbello faced her own fibroid nightmare—one the size of a grapefruit. 'When I found out it was 16 centimeters, I thought surgery was my only option. I didn't have insurance, I didn't know where to turn. They even wanted to put me on a menopause-inducing hormone, Lupron. I was terrified.' Then Fibroid Fighters stepped in. 'They answered every question, didn't rush me, and gave me hope—even about having kids someday,' she said. After undergoing UFE, she was back in the gym within a week. 'With surgery, you have to have a C-section. With embolization, you can give birth naturally. The recovery is night and day.' Sorbello is now competing on The Challenge: Vets vs. New Threats and hinted at a new Fox project premiering this fall. But she admits to one bad habit: 'I'm highly addicted to sugar. Fudge brownies are my crack,' she laughed. Dr. Yan Katsnelson's vision for Fibroid Fighters combines cutting-edge medical technology with patient-centered care. He aims to educate women on non-surgical options and reduce the link between fibroids and more serious health risks, including infertility and cardiovascular disease. With his foundation, he seeks to empower women to make informed decisions, improve outcomes, and prevent unnecessary hysterectomies. The evening concluded with an intimate concert featuring Tweet and fellow R&B powerhouse LaTocha of Xscape, leaving attendees inspired by both music and advocacy. As Dr. Katsnelson reminded the crowd, 'Knowledge is power, and awareness is the first step toward better health for every woman.' You can check out the whole conversation with Shay, Cynthia, Toya and Cara Maria in the video below Source: Jazmyn Summers / Jazmyn Summers Article by Jazmyn Summers. You can hear Jazmyn every morning on 'Jazmyn in the Morning 'on Sirius XM Channel 362 Grown Folk Jamz . Subscribe to J azmyn Summers' YouTube . Follow her on Facebook and Instagram. LIKE US ON FACEBOOK . FOLLOW US ON INSTAGRAM & TWITTER . SUBSCRIBE TO OUR YOUTUBE . STAY INFORMED! CLICK HERE TO SIGN UP FOR OUR NEWSLETTER! HEAD TO THE HOMEPAGE SEE ALSO

Nvidia-Led Tech Slide Cracks Summer Calm in Stocks: Markets Wrap
Nvidia-Led Tech Slide Cracks Summer Calm in Stocks: Markets Wrap

Bloomberg

time28 minutes ago

  • Bloomberg

Nvidia-Led Tech Slide Cracks Summer Calm in Stocks: Markets Wrap

Wall Street's summer calm cracked as a selloff in big tech dragged down stocks, underscoring the American market's narrow reliance on a handful of growth giants. The Nasdaq 100 slid 1.4% — its second-worst drop since April's tariff shock — led by a rout in Nvidia Corp. That pressure overwhelmed gains in over 350 shares in the S&P 500, exposing the fragility of an index propped up by megacaps. Home Depot Inc. 's results lifted big-box retailers, while Intel Corp. jumped as the US is ironing out details of a deal to take a 10% stake in the chipmaker.

Palantir Stock is ‘Anomalously Bullish' Says CEO Alex Karp, Because Ongoing AI ‘Revolution' Is Resulting In ‘a Perfect Time for Palantir'
Palantir Stock is ‘Anomalously Bullish' Says CEO Alex Karp, Because Ongoing AI ‘Revolution' Is Resulting In ‘a Perfect Time for Palantir'

Yahoo

time39 minutes ago

  • Yahoo

Palantir Stock is ‘Anomalously Bullish' Says CEO Alex Karp, Because Ongoing AI ‘Revolution' Is Resulting In ‘a Perfect Time for Palantir'

Palantir Technologies (PLTR) crossed a historic milestone in the second quarter of 2025, reporting its first-ever billion-dollar quarter. Revenue surged nearly 48% year-over-year to approximately $1.004 billion, easily beating Wall Street's expectations of roughly $937–940 million. Adjusted earnings per share came in at $0.16, topping consensus forecasts of $0.14, while adjusted operating margins climbed to an impressive 46%. Free cash flow soared to $569 million, representing a margin of 57%, and the company posted GAAP net income of about $327 million, or a 33% net margin. Palantir's Rule of 40 score — a key measure of growth and profitability — hit a remarkable 94%, underlining its rare balance of aggressive expansion and strong operational efficiency. The company's balance sheet remains robust, with a cash and short-term investment reserve of approximately $6 billion. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Powell, Trump Talks and Other Can't Miss Items this Week 'My Kid Will Never Ever Be Smarter Than an AI': OpenAI's Sam Altman Warns Most Kids Won't Know a World Without AI Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. A closer look at the numbers reveals that Palantir's U.S. business is powering much of the momentum. Domestic revenue surged 68% to $733 million, with U.S. commercial revenue skyrocketing 93% to $306 million and U.S. government revenue climbing 53% to $426 million. Internationally, Palantir continues to serve a growing base of major commercial clients in Europe and high-value government partners outside the United States, though CEO Alex Karp made clear that the company's most transformative work is occurring in its home market. Total Contract Value (TCV) rose 140% year-over-year to $2.3 billion, driven in part by a 222% jump in U.S. commercial TCV to $843 million. Off the back of these results, Palantir raised its full-year guidance to $4.14-4.15 billion, with U.S. commercial revenues now expected to surpass $1.3 billion — an increase of over 85% from the prior year. On the company's earnings call, Karp delivered one of his most emphatic visions to date, framing Palantir's success not just as a business story, but as part of a broader national transformation. He pointed to key offerings such as Ontology, Foundry, and Maven as being 'on the front line' of what he called 'a perfect time for Palantir' and 'a revolution in The United States of America.' While acknowledging the importance of Palantir's international partnerships, Karp cast the company's mission as fundamentally American, fueled by advances in AI, semiconductors, and large language models. He described Palantir as 'anomalously bullish' on every facet of U.S. life, with a particular focus on the country's blue-collar workforce. To a striking extent, Karp's remarks centered on AI as an 'agency-enhancing revolution.' He emphasized that Palantir's software is enabling workers without college degrees — often those in manual or industrial roles — to create as much, and in some cases more, value than formally educated professionals. To that end, Palantir plans to partner with labor leaders to develop new ways for workers to earn AI-enhanced incomes, effectively arming the working class with cutting-edge digital tools. This vision of democratizing access to AI capabilities, he suggested, is reflected in Palantir's financial performance: its strong unit economics flow downstream to its clients, who then seek to integrate those efficiencies into their own operations. Market reaction to the blowout results was swift. Palantir shares jumped 7.8% in post-earnings trading, pushing the stock's year-to-date gain above 130% and cementing it as the best-performing stock in the S&P 500 Index ($SPX) this year. Analysts lauded the combination of rapid revenue growth, widening margins, and expanding commercial adoption. Still, some caution remains on Wall Street, with Palantir's lofty valuation — pegged at over 400 times forward earnings — raising questions about the sustainability of such torrid growth. For now, however, Palantir is firing on all cylinders. The company stands at the crossroads of advanced AI deployment, surging demand from both government and private sectors, and a narrative that blends corporate success with national renewal. In Karp's words, the U.S. is not just Palantir's largest market — it is the arena for an AI-driven industrial renaissance, one in which the benefits of technology extend beyond boardrooms and into the hands of America's working class. On the date of publication, Caleb Naysmith did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store